A new COVID-19 variant, designated XEC, is rapidly spreading across the globe, particularly in Europe. Preliminary findings suggest that XEC may transmit more easily than previous variants. However, experts indicate that this variant exhibits similarities to earlier strains, and existing vaccines continue to be effective against it. Here’s what we know about the XEC variant so far.
Overview of the COVID-19 XEC Variant
The XEC variant is a genetic combination of two other SARS-CoV-2 variants, KP.3.3 and KS.1.1. This new variant emerged when these viruses co-infected the same host, allowing for genetic material exchange.
XEC is an offshoot of the Omicron variant, which first appeared in South Africa in 2021. Experts describe XEC as a descendant of Omicron, noted for its high transmissibility and a tendency to cause less severe illness compared to earlier SARS-CoV-2 strains.
Identification and Spread of XEC
The XEC variant was identified in August from COVID-19 samples collected in Berlin two months earlier, with the earliest instances traced back to Italy in May. These cases were not reported to international databases until September.
Current Case Numbers of XEC
According to reports, over 600 cases of the XEC variant have been documented in 27 countries, including the UK, Germany, Canada, and the US. However, experts caution that the actual number may be higher due to inconsistent reporting across countries.
In Europe, XEC has been identified in at least 13 countries. Recent data indicates that it represents approximately 8% of sequenced samples on the continent this month, up from 4% in August. The dominant variant in Europe remains KP.3.1.1, comprising 48% of samples.
XEC is most prevalent in France, accounting for about 21% of sequenced samples and also holds significant presence in Germany and the UK, at 15% and 8%, respectively. In the US, it currently represents around 1% of cases, though it has not yet been included in the official variant tracker.
Symptoms Associated with XEC
The symptoms of the XEC variant appear consistent with those of other COVID-19 variants, including fever, sore throat, cough, and muscle aches. Experts remain vigilant for any potential distinctive symptoms but currently expect them to align with past variants.
Potential Risks of XEC
Experts assert that the XEC variant does not seem to pose a greater risk or severity than previous variants. The World Health Organization has yet to classify it as a variant of concern, as it shares similarities with other Omicron subvariants known to cause milder illness.
Transmissibility of XEC
While it is too soon to definitively determine the transmissibility of XEC, its increasing prevalence among existing variants suggests it may possess characteristics that facilitate ease of spread. Preliminary analysis suggests XEC may become the dominant strain in Europe and the UK by October, with similar trends anticipated in the US and Canada.
Efficacy of Vaccines against XEC
The reassuring news is that current COVID-19 vaccines are expected to remain effective against the XEC variant, as they target Omicron subvariants. Health authorities encourage individuals aged six months and older to receive updated COVID-19 boosters if they haven’t done so this year.
In conclusion, experts emphasize that there is no need for alarm regarding XEC. The variant is evolving similarly to earlier strains, and health responses should remain consistent. As stated by experts, “It appears to be following the same pattern as past variants.”
Topics:
